AYTU BioPharma Inc (AYTU)

Form 8-K - Current report

Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026

DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical...

Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results

EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding...

Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026

DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Total net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at...

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a...

Form 8-K - Current report

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a...

Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA

EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies...